GPS Wealth Strategies Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

GPS Wealth Strategies Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-47	Closed	-$3.09K	–	1523
2024 Q4	$3.09K	Buy	+47	New	+$3.15K	﹤0.01%	1175
2023 Q3	–	Sell	-6	Closed	-$520	–	1285
2023 Q2	$520	Hold	6	–	–	﹤0.01%	1192
2023 Q1	$583	Buy	+6	New	+$622	﹤0.01%	1191
2022 Q4	–	Sell	-6	Closed	-$1K	–	226
2022 Q3	$1K	Hold	6	–	–	﹤0.01%	1066
2022 Q2	$0	Hold	6	–	–	﹤0.01%	1108
2022 Q1	$0	Hold	6	–	–	﹤0.01%	1044
2021 Q4	$1K	Sell	6 -12	-67%	-$990	﹤0.01%	1008
2021 Q3	$1K	Hold	18	–	–	﹤0.01%	976
2021 Q2	$2K	Hold	18	–	–	﹤0.01%	952
2021 Q1	$1K	Buy	+18	New	+$1.47K	﹤0.01%	895

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GPS Wealth Strategies Group's BMRN Position: Q1 2025 in Review

GPS Wealth Strategies Group sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2025, closing a stake of 47 shares — an estimated $3.09K sold.

GPS Wealth Strategies Group first reported a position in BMRN in Q1 2021 and held it in 10 quarters. The position peaked at $3.09K in Q4 2024. 584 funds tracked by Wall St. Rank hold BMRN as of Q1 2025.

GPS Wealth Strategies Group reported no remaining BioMarin Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
GPS Wealth Strategies Group sold 47 BioMarin Pharmaceuticals shares in Q1 2025, an estimated $3.09K.
GPS Wealth Strategies Group first reported a position in BioMarin Pharmaceuticals in Q1 2021 and held it in 10 quarters.
GPS Wealth Strategies Group's BioMarin Pharmaceuticals position peaked at $3.09K in Q4 2024.
584 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2025.

Based on GPS Wealth Strategies Group's 13F filing for Q1 2025, filed 15 Apr 2025.